EX-10.49 4 a12-8655_1ex10d49.htm EX-10.49u.s. Co-Promotion Agreement • May 5th, 2020 • New York
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Addendum to September 19, 2002u.s. Co-Promotion Agreement • July 31st, 2008 • Amylin Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Addendum to the U.S. Co-Promotion Agreement (the “Addendum”) is made effective as of the 8th day of May, 2008 (the “Effective Date”) by and between Amylin Pharmaceuticals, Inc. (“Amylin”), a Delaware corporation having its principal place of business at 9360 Towne Center Drive, San Diego, California, 92121.
AMENDED AND RESTATED U.S. CO-PROMOTION AGREEMENTu.s. Co-Promotion Agreement • November 13th, 2014 • Veracyte, Inc. • Services-medical laboratories • New York
Genzyme Corporation, with offices located at 500 Kendall Street, Cambridge, Massachusetts 02142 (hereinafter referred to as “Genzyme”)
BY AND BETWEEN ZYMOGENETICS, INC. AND BAYER HEALTHCARE LLC EFFECTIVE AS OF JUNE 18, 2007 the Securities and Exchange Commission pursuant to a request for confidential treatment.u.s. Co-Promotion Agreement • August 1st, 2007 • Zymogenetics Inc • Biological products, (no disgnostic substances) • New York
THIS U.S. CO-PROMOTION AGREEMENT is made as of the 18th day of June, 2007 (the “Effective Date”) by and between ZymoGenetics, Inc., a corporation organized and existing under the laws of Washington State, U.S.A. (“ZGEN”), and Bayer HealthCare LLC, a limited liability company organized and existing under the laws of Delaware (“Bayer”). ZGEN and Bayer are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Amendment to U.S. Co-Promotion Agreementu.s. Co-Promotion Agreement • March 1st, 2010 • Zymogenetics Inc • Biological products, (no disgnostic substances)
This amendment (the “Amendment”) to the U.S. Co-Promotion Agreement (the “Agreement”) by and between ZymoGenetics, Inc. (“ZGEN”) and Bayer HealthCare LLC (“Bayer”) effective as of June 18, 2007 is made the 1st day of January 2010 (the “Effective Date”) by and among ZGEN, Bayer and ZymoGenetics, LLC, ZGEN’s assignee under the Agreement (“Zymo”). Capitalized terms not otherwise defined herein shall have those meanings set forth in the Agreement. The term, “Party” shall mean Bayer, ZGEN or Zymo and the term, “Parties” means all of them.
BY AND BETWEENu.s. Co-Promotion Agreement • October 3rd, 2002 • Amylin Pharmaceuticals Inc • Pharmaceutical preparations • New York
U.S. CO-PROMOTION AGREEMENT AFFYMAX, INC. and TAKEDA PHARMACEUTICALS U.S.A., INC. February 24, 2012u.s. Co-Promotion Agreement • July 2nd, 2012 • Affymax Inc • Pharmaceutical preparations • New York
Unless otherwise mutually agreed by the Parties, the Parties will deploy resources as set forth in Exhibit A-1 and Exhibit C (Summary of Peginesatide Commercial and Medical Affairs Roles and Responsibilities) including the following: [ * ] shall deploy [ * ] as outlined in Exhibit C.
